On May 11, 2020, Airway Therapeutics announced a filing with the Respiratory Diseases Branch of the National Institutes of Health to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).

Airway is advancing AT-100 – an engineered version of an endogenous protein – that has been shown in preclinical studies to safely reduce inflammation and infection while modulating the immune response across a range of respiratory diseases inside and outside the lung.